Abstract
Atherosclerotic cardiovascular disease (ASCVD) remains an important contributor of morbidity and mortality in patients with chronic kidney disease (CKD). CKD is recognized as an important risk enhancer that identifies patients as candidates for more intensive low-density lipoprotein (LDL) cholesterol lowering. However, there is controversy regarding the efficacy of lipid-lowering therapy, especially in patients on dialysis. Among patients with CKD, not yet on dialysis, there is clinical trial evidence for the use of statins with or without ezetimibe to reduce ASCVD events. Newer cholesterol lowering agents have been introduced for the management of hyperlipidemia to reduce ASCVD, but these therapies have not been tested in the CKD population except in secondary analyses of patients with primarily CKD stage 3. This review summarizes the role of hyperlipidemia in ASCVD and treatment strategies for hyperlipidemia in the CKD population.
| Original language | English |
|---|---|
| Pages (from-to) | 479-489 |
| Number of pages | 11 |
| Journal | Cardiovascular Drugs and Therapy |
| Volume | 35 |
| Issue number | 3 |
| DOIs | |
| State | Published - Jun 2021 |
Keywords
- Atherosclerotic cardiovascular disease
- Chronic kidney disease
- Dyslipidemia
- End-stage renal disease
- PCSK9 inhibitors
Fingerprint
Dive into the research topics of 'Concepts and Controversies: Lipid Management in Patients with Chronic Kidney Disease'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver